Cibus, Inc. (CBUS)
NASDAQ: CBUS · Real-Time Price · USD
1.410
-0.060 (-4.08%)
Aug 15, 2025, 4:00 PM - Market closed
Cibus Revenue
Cibus had revenue of $933.00K in the quarter ending June 30, 2025, with 11.34% growth. This brings the company's revenue in the last twelve months to $4.85M, up 63.66% year-over-year. In the year 2024, Cibus had annual revenue of $4.26M with 134.56% growth.
Revenue (ttm)
$4.85M
Revenue Growth
+63.66%
P/S Ratio
9.23
Revenue / Employee
$30,478
Employees
159
Market Cap
76.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.26M | 2.45M | 134.56% |
| Dec 31, 2023 | 1.82M | 1.66M | 1,057.32% |
| Dec 31, 2022 | 157.00K | -25.83M | -99.40% |
| Dec 31, 2021 | 25.99M | 2.14M | 8.96% |
| Dec 31, 2020 | 23.85M | 16.56M | 226.91% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CBUS News
- 2 days ago - Cibus, Inc. (CBUS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Cibus Reports Second Quarter Financial Results and Provides Year-to-Date Business Update for 2025 - GlobeNewsWire
- 12 days ago - Cibus to Report Second Quarter 2025 Financial Results on August 14, 2025 After the Market Close and Host Conference Call - GlobeNewsWire
- 7 weeks ago - The U.S. Food and Drug Administration Completes Review of Cibus' Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed - GlobeNewsWire
- 2 months ago - Cibus and John Innes Centre Announce Ongoing Collaboration with Potential to Revolutionize Fertilizer Use in Farming - GlobeNewsWire
- 2 months ago - Cibus, Inc. Announces Closing of $27.5 Million Public Offering - GlobeNewsWire
- 2 months ago - USDA Designates Cibus' Herbicide Tolerance Canola Trait HT2 as Not Regulated Under USDA's Biotechnology Regulations - GlobeNewsWire
- 2 months ago - Cibus, Inc. Announces Pricing of $27.5 Million Public Offering - GlobeNewsWire